Pharmaceutical

PRO-1107 by ProfoundBio Suzhou for Solid Tumor: Likelihood of Approval

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Solid Tumor.

Apr 21, 2024 - 00:00
PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Solid Tumor.
Read the original article

Tags:

Previous Article

PRO-1107 by ProfoundBio Suzhou for Endometrial Cancer: Likelihood of Approval

Next Article

PRO-1107 by ProfoundBio Suzhou for Bladder Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

CPHI Europe: Targeting supply chain bottlenecks key for cell and gene therapies

CPHI Europe: Targeting supply chain bottlenecks key for...

Oct 12, 2024

STAT+: David Liu startup to focus on getting CRISPR therapy to hard-to-reach cells

STAT+: David Liu startup to focus on getting CRISPR the...

Sep 18, 2023

STAT+: Hospitals try a new pitch to investors: other ways of making money

STAT+: Hospitals try a new pitch to investors: other wa...

Jan 8, 2024